Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper - NETs

1160O - An international open-label study on safety and efficacy of 177Lu-satoreotide tetraxetan in somatostatin receptor positive neuroendocrine tumours (NETs): An interim analysis


20 Sep 2020


Proffered Paper - NETs


Guillaume Nicolas


Annals of Oncology (2020) 31 (suppl_4): S711-S724. 10.1016/annonc/annonc281


G.P. Nicolas1, C. Ansquer2, N.P. Lenzo3, H. Grønbæk4, A. Haug5, S. Navalkissoor6, J. Beauregard7, N. Germann8, S. McEwan9, D. Wild1, R.J. Hicks10

Author affiliations

  • 1 Division Of Nuclear Medicine And Neuroendocrine And Endocrine Tumour Centre, University Hospital Basel, 4031 - Basel/CH
  • 2 Service De Médecine Nucléaire, CHU-Hôtel Dieu, 44093 - Nantes/FR
  • 3 Theranostics, GenesisCare, 6158 - East Fremantle/AU
  • 4 Department Of Hepatology & Gastroenterology, Aarhus Universitetshospital, 8200 - Aarhus/DK
  • 5 Department Of Biomedical Imaging And Image-guided Therapy, Medical University of Vienna, 1090 - Vienna/AT
  • 6 Neuroendocrine Tumour (net) Unit, Nuclear Medicine, Royal Free London, NW32QG - London/GB
  • 7 Medical Imaging, CHU de Québec-Université Laval, G1R 2J6 - Quebec/CA
  • 8 Gps, Ipsen Innovation France, 91140 - Les Ulis/FR
  • 9 Systemic Radiotherapy (srt), Ipsen, L4W 5N5 - Mississauga/CA
  • 10 Cancer Imaging, Peter MacCallum Cancer Centre, 3000 Vic - Melbourne/AU


Login to access the resources on OncologyPRO.

Abstract 1160O


177Lu-satoreotide tetraxetan (177Lu-IPN01072), a novel somatostatin receptor 2 (SSTR2) antagonist, showed promising efficacy in patients with progressive NETs associated with myelotoxicity at 7.4 GBq/cycle administered activity. This phase I/II study evaluates the safety and preliminary efficacy of this agent by adjusting treatment regimen to limit radiation dose to bone marrow and kidneys.


Eligibility included progressive grade 1/2 NETs. Phase I comprises parts A and B. Part A involved, subject to toxicity, planned administration of 3 cycles of 4.5 GBq of 177Lu-satoreotide tetraxetan with a peptide mass of 300 μg and enrolled 15 patients. After safety evaluation, part B proceeded with the radioactivity/peptide mass ratio per cycle being escalated up to 6.0 GBq/300 μg or 4.5 GBq/300-1300 μg; 20 patients were enrolled at the interim analysis (IA) cut-off date.


Previous treatments of the 35 enrolled patients included surgery (69%), chemotherapy (20%), radiotherapy (14%), and prior or concomitant somatostatin analogues (77%). At the IA cut-off date, 28 had completed treatment, and 7 were still receiving planned cycles. Of these 28 patients, 22 (78.6%) had received 3 cycles with median cumulative radioactivity of ∼13 GBq, and 6 (21.4%) discontinued treatment. Overall, grade 3/4 related haematological adverse events (AEs) were reported in 12 patients (34.3%) with lymphopenia/decrease in lymphocyte counts in 6 (17.1%), thrombocytopenia/decrease in platelets count in 5 (14.3%), neutropenia in 2 (5.7%) and anemia in 1 (2.9%). No grade 3/4 renal toxicities were reported. For the 20 patients with adequate follow-up, disease control rate (DCR) at 12 months was 90% (95% CI: 68.3% - 98.8%).


This IA suggests that 177Lu-satoreotide tetraxetan has an acceptable safety profile in patients with NET using a lower administered activity per cycle than in earlier studies with this agent or current protocols using SSTR2 agonists. Promising efficacy results encourage the pursuit of its development in this indication.

Clinical trial identification

EudraCT: 2015-002867-41; NCT02592707.

Editorial acknowledgement

Partner 4 Health, France, provided medical writing support in accordance with Good Publication Practice (GPP3) guidelines.

Legal entity responsible for the study





C. Ansquer: Advisory/Consultancy: Advanced Accelerator Applications - France. N. Germann, S. McEwan: Full/Part-time employment: Ipsen. D. Wild: Advisory/Consultancy: Ipsen. R.J. Hicks: Advisory/Consultancy, Shareholder/Stockholder/Stock options, with proceeds donated to my institution: Telix Pharmaceuticals. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings